Sex-related differences in the pharmacokinetics of oral ciprofloxacin

被引:24
作者
Overholser, BR
Kays, MB
Forrest, A
Sowinski, KM
机构
[1] Purdue Univ, Dept Pharm Practice, Sch Pharm & Pharmacal Sci, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA
[3] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY USA
关键词
oral pharmacokinetics; ciprofloxacin; drug exposure; sex differences;
D O I
10.1177/0091270004266843
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The oral pharmacokinetics of ciprofloxacin were studied in healthy volunteers to assess the influence of sex on its disposition. Subjects (8 males, 7 females) received a single oral dose of ciprofloxacin 750 mg, blood and urine samples were collected, and ciprofloxacin concentrations were determined. A two-compartment open-model with two or three absorption phases, each one having a fitted independent lag time, best fit the data using a weighted least squares estimator. Univariate and multivariate regression analyses were performed to determine the influence of renal function, Weight, and subject sex on the oral clearance (CLS/F) and apparent steady-state volume of distribution (V-ss/F) of ciprofloxacin. Females had a median C-max of ciprofloxacin that was 30% greater than males and a significantly smaller median (range) V-ss/F: 81.1 (44.8-111.6) versus 170.9 (140.9-213.4), respectively (p < 0.01). In addition, females had increased exposure to ciprofloxacin, with a slower median (range) CLS/F of 28.3 L/h (24.5-33.4) compared to 44.4 L/h (41.4-53.7) for males (p < 0.01). Regression analyses revealed that subject sex was the only significant predictor of CLS/F (p < 0.001), but both bodyweight (p = 0.04) and subject sex (p < 0.005) were significant predictors of V-ss/F. Fixed oral doses of ciprofloxacin will lead to higher maximum concentration and total drug exposure in females compared to males and do not appear to be solely related to weight-based differences.
引用
收藏
页码:1012 / 1022
页数:11
相关论文
共 45 条
[1]  
AKAIKE H, 1976, MATH SCI, V153, P5
[2]   Clinical role of protein binding of quinolones [J].
Bergogne-Bérézin, E .
CLINICAL PHARMACOKINETICS, 2002, 41 (10) :741-750
[3]   Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers [J].
Bertino, JS ;
Nafziger, AN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :789-791
[4]   The prophylaxis and treatment of anthrax [J].
Brook, I .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (05) :320-325
[5]  
CAKMAKCI M, 1992, DRUG EXP CLIN RES, V18, P299
[6]   Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells [J].
Cavet, ME ;
West, M ;
Simmons, NL .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (08) :1567-1578
[7]   Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects [J].
Chien, SC ;
Chow, AT ;
Natarajan, J ;
Williams, RR ;
Wong, FA ;
Rogge, MC ;
Nayak, RK .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1562-1565
[8]   Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers [J].
Chow, AT ;
Fowler, C ;
Williams, RR ;
Morgan, N ;
Kaminski, S ;
Natarajan, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2122-2125
[9]   PHARMACOKINETICS AND TISSUE PENETRATION OF CIPROFLOXACIN [J].
CRUMP, B ;
WISE, R ;
DENT, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (05) :784-786
[10]   Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein [J].
Cummins, CL ;
Wu, CY ;
Benet, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) :474-489